2CBFly-NBOMe (NBOMe-2C-B-FLY, Cimbi-31) is a compound indirectly derived from the phenethylamine hallucinogen 2C-B, and related to benzodifurans like 2C-B-FLY and N-benzylphenethylamines like 25I-NBOMe. It was discovered in 2002,[1] and further researched by Ralf Heim at the Free University of Berlin,[2] and subsequently investigated in more detail by a team at Purdue University led by David E. Nichols.[3] It acts as a potent partial agonist for the 5-HT2A serotonin receptor subtype.[4][5][6]
Names | |
---|---|
Preferred IUPAC name
2-(8-Bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b′]difuran-4-yl)-N-[(2-methoxyphenyl)methyl]ethan-1-amine | |
Identifiers | |
| |
3D model (JSmol)
|
|
Abbreviations | 2CBFly-NBOMe |
ChemSpider |
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H22BrNO3 | |
Molar mass | 404.298 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is ?)
Infobox references
|
Analogues and derivatives of 2C-B:
25-N:
25-NM:
Other:
This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[11]
2CBFly-NBOMe is a controlled substance in Vermont as of January 2016.[12]